Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
806.78M | 937.82M | 698.80M | 538.59M | 380.77M | Gross Profit |
806.78M | 872.34M | 654.12M | 506.26M | 361.82M | EBIT |
-302.57M | -349.40M | -439.93M | -374.94M | -397.88M | EBITDA |
-120.46M | -330.34M | -367.78M | -374.44M | -297.00M | Net Income Common Stockholders |
-363.30M | -626.60M | -559.02M | -523.90M | -438.16M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
1.14B | 876.74M | 410.70M | 773.38M | 1.10B | Total Assets |
1.71B | 1.90B | 1.71B | 1.94B | 2.21B | Total Debt |
389.30M | 2.23B | 703.63M | 431.43M | 420.44M | Net Debt |
-390.41M | 1.64B | 292.92M | -341.94M | 211.63M | Total Liabilities |
2.80B | 2.71B | 2.05B | 1.94B | 1.73B | Stockholders Equity |
-1.10B | -818.55M | -347.09M | 1.44M | 481.98M |
Cash Flow | Free Cash Flow | |||
-114.19M | -279.04M | -509.11M | -336.66M | -250.05M | Operating Cash Flow |
-107.69M | -158.42M | -356.65M | -251.33M | -194.07M | Investing Cash Flow |
44.18M | -176.74M | 290.18M | 219.18M | -561.55M | Financing Cash Flow |
255.87M | 646.40M | 167.95M | 20.88M | 668.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | $3.87B | 7.50 | 33.08% | ― | 91.12% | ― | |
61 Neutral | $3.42B | ― | -35.56% | ― | -41.66% | -180.15% | |
54 Neutral | $3.52B | ― | -51.57% | ― | 730.42% | 31.63% | |
53 Neutral | $5.24B | 3.28 | -44.98% | 2.81% | 16.82% | -0.32% | |
53 Neutral | $3.73B | ― | -34.19% | ― | -17.87% | -1.89% | |
52 Neutral | $4.05B | ― | -418.97% | ― | 48.88% | 39.30% | |
46 Neutral | $3.22B | ― | -386.33% | ― | 33.46% | 26.72% |
PTC Therapeutics reported strong financial results for the first quarter of 2025, with a total net product and royalty revenue of $190 million. The company highlighted a positive CHMP opinion for Sephience, which is expected to enhance its global market launch. PTC’s cash position of over $2 billion supports its commercial and R&D activities, aiming for cashflow breakeven without additional capital. The company also updated its full-year 2025 financial guidance, anticipating revenue between $650 million and $800 million, driven by existing and potential new product launches.
PTC Therapeutics announced positive results from its Phase 2 PIVOT-HD study of PTC518 for Huntington’s disease, achieving the primary endpoint of reducing blood Huntingtin protein levels. The study showed favorable safety and tolerability, with dose-dependent clinical benefits observed over 12 and 24 months, potentially positioning PTC518 as a disease-modifying therapy for Huntington’s disease.
On March 28, 2025, PTC Therapeutics announced that the European Commission adopted the negative opinion of the Committee for Medicinal Products for Human Use, deciding not to renew the conditional marketing authorization for Translarna (ataluren) in the European Economic Area. Despite this setback, the European Commission noted that individual EU member states could still allow the continued use of Translarna, highlighting its safety and benefits for patients with nonsense mutation Duchenne muscular dystrophy, a rare and severe genetic disorder.